Navigation Links
Cerulean Completes Enrollment of Randomized Phase 2 Study of CRLX101 in Non-Small Cell Lung Cancer
Date:7/2/2012

so am pleased that, on the heels of this milestone, we are exploring the breadth of the CRLX101 opportunity by initiating additional studies in high priority target indications."

About CRLX101 
CRLX101 is an investigational anti-cancer agent that is a dual inhibitor of topoisomerase 1 and hypoxia-inducible factor-1 alpha.  CRLX101 is a dynamically tumor-targeted nanopharmaceutical designed to concentrate in tumors, prolonging drug exposure at the site of action.  Significant anti-tumor activity has been observed across a wide range of cancers in animal models.  CRLX101 is currently in Phase 2 clinical development.  More information on CRLX101 clinical studies can be found at www.clinicaltrials.gov.

About Cerulean Pharma Inc.
Cerulean Pharma Inc. is a clinical-stage company specializing in the development of dynamically tumor-targeted nanopharmaceuticals.  Cerulean is applying its proprietary nanopharmaceutical platform to advance a new class of therapeutic agents to address significant unmet medical needs.  With an initial focus in oncology, the Company's technology platform can be applied to a wide range of drug molecules, ranging from small molecules to peptides and RNAs.  Cerulean is privately financed and funded by experienced healthcare investors, including Polaris Venture Partners, Venrock, Lilly Ventures, Lux Capital, Bessemer Venture Partners, and CVF, LLC.  Cerulean is located in Cambridge, Massachusetts.  For more information, please visit the Company's website at http://www.ceruleanrx.com.

Media Contacts:

Schwartz MSL
Benjamin Navon/Kathy Vigneault
cerulean@schwartzmsl.com 
+1 781-684-0770


'/>"/>
SOURCE Cerulean Pharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Biocartis Completes EUR 71 Million (USD 100 Million) Series C Fund Raising
2. InnoPharma Completes $15 Million Series A Financing
3. Aratana Therapeutics Completes $15 Million Series B Financing
4. CeNeRx BioPharma Completes $4.85 Million Financing
5. PDL BioPharma Completes Regular Quarterly Dividend Payment
6. MiMedx Group Completes $5,000,000 Private Placement
7. goBalto Completes a Successful FDA 21 CFR Part 11 Compliance Audit
8. Auxogyn Completes $20 Million In Series A Funding
9. CitiusTech Completes Another Milestone Year: Revenues Grow by 59% in 2011
10. GeneLink Biosciences Completes Sale of GeneWize Life Sciences
11. Ikaria® Completes Patient Enrollment in Pivotal Phase III Trial for Bronchopulmonary Dysplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... (PRWEB) June 18, 2013 The human skin ... skin as an important human body part. Similar to the ... in order to function, repair and grow. Recent reports from ... and supplements, is just as important as other life supporting ... to aid in skin cell reproduction, increase the appearance of ...
(Date:6/18/2013)... -- regulated information — Global biopharmaceutical company UCB, Inc. and ... launch of a new Pledge campaign for people with ... empowers the millions of Americans living with ... commitment to demand more: greater understanding of the condition, ... partial-onset seizure control.  More information is available at ...
(Date:6/18/2013)... , June 18, 2013  Techne Corporation (NASDAQ: ... it has agreed to acquire 100% ownership of ... Inc. (Bionostics).  Bionostics is a global leader in ... that verify the proper operation of in ... point of care blood glucose and blood gas ...
(Date:6/18/2013)... As a leading provider of telehealth ... release of their infographic - " 8 New ... goal was to leverage an information graphic to ... 3.0 and mHealth.The infographic features a list of ... the fitness industry in unimaginable ways; turning science ...
Breaking Biology Technology:Natural Acne Remedies Through Diet, Probiotic Action Shares New Insight on What Foods May Help Lead to Clear Skin 2Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 2Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 3Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 4Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 5Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 6Techne Corporation Announces Acquisition Agreement 2Techne Corporation Announces Acquisition Agreement 3Techne Corporation Announces Acquisition Agreement 4Techne Corporation Announces Acquisition Agreement 5MeMD, Inc Releases Infographic Featuring the Top Eight Technologies that are Revolutionizing Health and Fitness Today 2
... WinnersDENVER, March 30 Cochlear Americas, the world,s ... winners of the 2009 Graeme Clark Scholarship awards. ... has recognized the remarkable achievements of individuals who ... small electronic device that can provide a sense ...
... leading campus recruitment company, has announced the official ... new website is designed for students, recent graduates, ... the biotechnology, pharmaceutical, and life sciences industries. With ... more people are considering a career in these ...
... support for expected Phase 3 programCRANBURY, N.J., March 28 ... today positive results from its ongoing Phase 2 extension ... Fabry disease. The results will be presented at ... Meeting in Tampa, FL. Phase 2 Extension ...
Cached Biology Technology:Cochlear Americas Provides Support for Cochlear Implant Recipients to Pursue Higher Education 2Cochlear Americas Provides Support for Cochlear Implant Recipients to Pursue Higher Education 3Cochlear Americas Provides Support for Cochlear Implant Recipients to Pursue Higher Education 4Cochlear Americas Provides Support for Cochlear Implant Recipients to Pursue Higher Education 5Recent Graduates Finding BioTech & Pharmaceutical Jobs Easier Than Ever With The Launch of CampusRXBio 2Recent Graduates Finding BioTech & Pharmaceutical Jobs Easier Than Ever With The Launch of CampusRXBio 3Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting 2Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting 3Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting 4Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting 5
(Date:6/18/2013)... been awarded a $394,300 grant from the Tarrant ... flow in the new facilities of the 150-mile ... associate professor of civil engineering, will investigate the ... the water in an effort to eliminate biological ... Adding monochloramine is widely practiced throughout the United ...
(Date:6/18/2013)... Obar, Ph.D., Department of Immunology and Infectious Diseases, Montana ... Young Investigator Award for his research on factors affecting ... , Obar earned his B.A. in Microbiology from ... complete his Ph.D. in Microbiology and Immunology from Dartmouth ... research in Edward Usherwood,s laboratory at the Geisel School ...
(Date:6/18/2013)... internationally recognized feline experts including veterinarians and feline scientists ... Lincoln, U.K. and Dr Ilona Rodan, Director of Cat ... Society of Feline Medicine (ISFM) and the American Association ... owners and those working with cats on how to ... new guidelines appear in the Journal of Feline ...
Breaking Biology News(10 mins):UT Arlington research to benefit quality, flow in 150-mile Integrated Pipeline 2The American Society for Microbiology honors Joshua Obar 2Feline behavior experts release guidelines to improve the welfare of cats 2
... rise, and the loss of sand dune plant habitats" ... to better understand the impacts of development and coastal ... the ever-shrinking strip of habitat between land and the ... simulated varying levels of sea-level rise to understand the ...
... body, a virus such as HIV invades body cells by ... inside the cell, the invading microbe's genetic material takes over, ... copies of the virus, which then spill out to invade ... once a virus begins fusing with a cell's membrane, infection ...
... dramatic reduction in the impact of malaria is in prospect ... Guinea early next year. Success in the trial would open ... with this debilitating and often fatal disease - over 500,000,000 ... Medical Research is collaborating with the Papua New Guinea Institute ...
Cached Biology News:Squeezing out dune plants 2Several minute intermediate stage in virus-cell fusion discovered; opportunity for drug development 2Several minute intermediate stage in virus-cell fusion discovered; opportunity for drug development 3Old drug, new tricks: Prospects for slashing the impact of malaria 2
Donor feline serum and plasma...
Consists of 4 separate 100mM solutions (ATP,GTP,CTP and UTP pH 7.5) as sodium salts. 98% Pure by HPLC...
HAS1 (C-14)...
Donor feline serum and plasma...
Biology Products: